Search

The article discusses an open-label, Phase 1 study focusing on the effects of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) on the pharmacokinetics of MK-8527 in healthy participants. The study aims to understand how MK-8527 behaves in the body over time and whether there are differences when taken alone or with FTC/TDF. The trial is set to enroll 20 participants and is expected to be completed by June 5, 2025. [Extracted from the article]

The article discusses a clinical trial, NCT06821698, conducted by Kaken Pharmaceutical Co. Ltd., focusing on the effects of KP-001 on the pharmacokinetics of rosuvastatin and caffeine, as well as the impact of fluvoxamine on KP-001 pharmacokinetics in healthy adult participants. The study is divided into three parts, each evaluating different aspects of drug interactions and metabolism. The trial aims to provide valuable insights into the interactions between these medications in the human body. [Extracted from the article]

A recent study conducted at Sichuan University in Chengdu, People's Republic of China, focused on the management of inactive hepatitis B surface antigen (HBsAg) carriers within the context of chronic hepatitis B. The research highlighted discrepancies between Eastern and Western guidelines regarding the definition and treatment of these carriers, emphasizing the importance of antiviral treatment in reducing disease progression and hepatocellular carcinoma risk. The study concluded that patient compliance is crucial for favorable outcomes, and further research on the long-term impacts of treatment is necessary. [Extracted from the article]

Researchers from the Second Affiliated Hospital of Anhui Medical University in China conducted a study on the impact of small hepatitis B surface protein mutations on occult hepatitis B infection (OBI). The study found that cells transfected with OBI-related mutation-containing plasmids had lower levels of HBsAg and accumulated in the endoplasmic reticulum, triggering an endoplasmic reticulum stress response. This ultimately led to reduced assembly and secretion of HBV virions. The findings suggest a potential mechanism for the pathogenesis of OBI through the UPR-ERAD pathway. [Extracted from the article]

The article discusses a Phase 1/2 clinical trial, NCT06818643, evaluating the safety and efficacy of MK-3120 in participants with advanced solid tumors that cannot be surgically removed. The study aims to assess the safety and tolerability of MK-3120 in treating these advanced solid tumors. The trial is not yet recruiting participants, with a primary completion date set for January 28, 2028. The study is interventional, with a randomized allocation and parallel intervention model, focusing on treatment for advanced solid tumors. [Extracted from the article]

The article discusses a clinical trial, NCT06812715, evaluating pirtobrutinib in treating relapsed/refractory Chronic Lymphocytic Leukaemia (CLL) patients who previously received zanubrutinib. The trial aims to assess the clonal dynamics of Bruton Tyrosine Kinase (BTK) mutations before, during, and after treatment with pirtobrutinib. The study involves various outcome measures, including overall response rate, time to response, duration of response, disease control rate, time to next treatment, progression-free survival, and overall survival. The trial is interventional, phase II, and involves a single-group treatment arm with recruitment status as not yet recruiting. [Extracted from the article]

The article discusses a clinical trial, NCT06816017, evaluating the safety, pharmacokinetics, and anti-tumor activity of intravesical eciskafusp alfa in combination with Bacillus Calmette-guerin (BCG) for BCG-unresponsive high-risk non-muscle invasive bladder cancer. The study aims to determine the efficacy of this combination therapy and plans to evaluate eciskafusp alfa in monotherapy based on positive interim results. The trial is not yet recruiting participants and is expected to be completed by October 31, 2030, with a primary completion date of October 31, 2028. [Extracted from the article]

The article discusses a Phase II clinical trial, NCT06817720, evaluating the efficacy and toxicity of olverembatinib monotherapy in patients with newly diagnosed Chronic Myeloid Leukemia in the chronic phase. The trial aims to assess various outcomes such as major molecular response rate, complete cytogenetic response rate, and toxicity of the treatment. The study is still in the recruitment phase, with eligibility criteria including age, disease stage, prior treatments, and organ function. The trial is being conducted in the United States and is led by Dr. Fadi Haddad from M.D. Anderson Cancer Center. [Extracted from the article]

The article discusses a clinical trial, NCT06804824, conducted by Vividion Therapeutics, Inc., to evaluate the safety, tolerability, and anti-tumor activity of VVD-159642, a RAS-PI3Ka inhibitor, in participants with advanced solid tumors. The study aims to assess the pharmacokinetics, pharmacodynamics, and preliminary efficacy of VVD-159642 as a single agent and in combination with sotorasib or trametinib. The trial is set to begin on March 1, 2025, with a primary completion date of August 1, 2027, and aims to enroll 220 participants with specific inclusion and exclusion criteria related to solid tumors and other health conditions. [Extracted from the article]

A study conducted in Zhejiang, People's Republic of China, focused on the clinical effects of entecavir on serum hyaluronic acid, laminin, and type IV collagen in patients with hepatitis B e-antigen-positive chronic hepatitis B. The research compared the outcomes of patients receiving entecavir monotherapy with those undergoing thymalfasin + entecavir combination therapy, showing significant differences in liver function indicators and immune function-related indicators. The study concluded that entecavir is highly effective in treating HBeAG-positive chronic hepatitis B and that combination therapy can alleviate clinical symptoms and prevent liver fibrosis. [Extracted from the article]

A recent study conducted at Mahidol University in Thailand focused on investigating the prevalence of hepatitis B virus (HBV) among patients with acute undifferentiated febrile illness (AUFI) at Tha Song Yang Hospital in Tak Province. The study found that 6.45% of AUFI patients tested positive for HBV infection, with genotypes C and B identified. Seroprevalence of antibodies against HBV core antigen and surface antigen was also observed. The researchers recommended vigilance for potential HBV infections in AUFI cases and suggested catch-up vaccination for individuals near the Thai border to reduce infection rates. [Extracted from the article]

A study conducted at Nanjing University in the People's Republic of China explored the coexisting patterns and significance of serum hepatitis B virus (HBV) RNA and traditional virological biomarkers in patients with treatment-naive chronic hepatitis B virus infection. The research found that serum HBV RNA levels correlated well with HBV DNA, HBeAg, and HBsAg levels, with variations across different patient groups. The study suggests that serum HBV RNA should be included in key index panels to accurately evaluate the natural history of HBV infection and the effects of antiviral treatment. [Extracted from the article]

The article discusses a clinical trial, NCT06803693, comparing the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The study aims to evaluate various outcomes such as progression-free survival, complete response rate, and overall survival. The trial is set to enroll 152 participants and is expected to be completed by December 31, 2028. [Extracted from the article]

The article discusses a Phase I clinical trial, NCT06807632, testing the safety and efficacy of valemetostat in combination with atezolizumab as maintenance therapy for patients with extensive-stage small cell lung cancer (SCLC). The study aims to determine the highest dose of valemetostat with minimal side effects and assess its effectiveness in treating SCLC. The trial is recruiting participants and is expected to be completed by January 31, 2027, with a focus on evaluating the primary outcome measure of determining the Phase II dose and progression-free survival. [Extracted from the article]

A clinical trial, NCT06797310, is being conducted to evaluate the effectiveness of baricitinib in treating acute alopecia areata (AA) with active hair shedding. Baricitinib has shown promise in chronic AA, but its impact on acute AA is uncertain. The study aims to assess the ability of baricitinib to reduce or halt hair shedding within 4-6 weeks in 30 patients with acute AA. Participants will receive 4 mg daily for 16 weeks, with follow-up visits scheduled over 52 weeks to monitor progress. This study will provide valuable insights into the management of acute AA with active hair shedding using baricitinib. [Extracted from the article]

The article discusses a Phase 2 clinical trial, NCT06788964, focusing on the safety and efficacy of Loncastuximab tesirine and Rituximab as a bridging therapy before standard-of-care chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed or refractory large B-cell lymphoma. The trial aims to evaluate the complete response rate, toxicity, adverse events, CD19 expression, disease control, and other outcomes in patients receiving this treatment regimen. The study is interventional, phase 2, and not yet recruiting participants, with a primary completion date of March 31, 2027. [Extracted from the article]

The article discusses a clinical trial, NCT06797635, focusing on new treatments for triple-negative breast cancer and hormone receptor-low positive/HER2 negative breast cancer. The study aims to evaluate the safety and efficacy of patritumab deruxtecan plus pembrolizumab with other anticancer agents in participants with high-risk early-stage breast cancer. The trial involves different treatment arms and outcome measures related to adverse events, pathological complete response rate, and survival. The study is not yet recruiting participants, with an enrollment target of 372 and a completion date of December 31, 2034. [Extracted from the article]

The article discusses a Phase 2 clinical trial, NCT06795399, comparing the effects of OPC-131461 and a placebo on blood N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with worsening heart failure. The trial aims to assess changes in NT-proBNP levels after 30 days of treatment. The study involves randomized, double-blind, placebo-controlled interventions with specific inclusion and exclusion criteria for participants. The trial is expected to last approximately 7 months, with a primary completion date of January 31, 2027. [Extracted from the article]

The article discusses a clinical trial, NCT06795906, conducted by AstraZeneca to evaluate the safety, pharmacokinetics, and pharmacodynamics of AZD8630 in adults with asthma on medium-to-high dose inhaled corticosteroids and long-acting beta-agonists. The study is randomized, placebo-controlled, double-blinded, and sponsor-unblinded. It aims to assess the effects of AZD8630 compared to a placebo over a 2-week period, with primary outcome measures focusing on adverse events and drug concentration levels. The trial is still in the recruitment phase, with an enrollment target of 24 participants and a completion date set for May 22, 2025. [Extracted from the article]

A Phase II clinical trial, NCT06789289, is being conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of TQC2938 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). The trial, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., aims to enroll 256 subjects and is expected to be completed by December 31, 2027. The study will assess the annualized incidence rate of acute exacerbations of COPD, safety and tolerability, lung function changes, and other outcomes related to COPD management. [Extracted from the article]

A recent study conducted at the Wuhan Blood Center in China examined the seroprevalence characteristics of hepatitis E virus (HEV) among blood donors with hepatitis B virus (HBV) infection. The research found that the reactivity rate of anti-HEV IgG was significantly higher in HBV-infected donors compared to normal donors, with age being identified as an independent risk factor. The study suggests that it is crucial to prioritize the prevention and treatment of HEV among HBV-infected donors to reduce the spread of the virus. [Extracted from the article]

A study conducted in Kyrgyzstan in 2022 evaluated the impact of the hepatitis B vaccination program on third-grade school children. The research found that the vaccination coverage for HepB BD and HepB3 was high, resulting in a very low HBsAg seroprevalence among vaccinated birth cohorts. The study highlights the success of the vaccination program in Kyrgyzstan and emphasizes the importance of maintaining high vaccination uptake to achieve the elimination of vertical transmission of hepatitis B in the country. [Extracted from the article]

The article discusses a clinical trial, NCT06780085, focusing on new treatments for metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been previously treated. The study aims to evaluate the effectiveness of two antibody drug conjugates (ADCs) compared to chemotherapy in treating NSCLC that did not respond to standard treatment. Researchers seek to assess the safety and efficacy of these treatments in patients with advanced lung cancer. The trial is set to begin on February 11, 2025, with a primary completion date of September 13, 2030. [Extracted from the article]

The article discusses a clinical trial, NCT06780098, focusing on new treatments for metastatic squamous non-small cell lung cancer (NSCLC). Standard treatments include immunotherapy and chemotherapy, but researchers are exploring antibody drug conjugates (ADCs) for cases where standard treatment is ineffective. The study aims to evaluate the effectiveness and safety of ADCs compared to chemotherapy in treating NSCLC. The trial is part of a larger umbrella master protocol (MK-3475-U01/KEYMAKER-U01) and is set to begin on February 11, 2025, with a primary completion date of September 13, 2030. [Extracted from the article]

The article discusses a single-arm phase II clinical study aiming to evaluate the effectiveness of HRS-4642 combined with nimotuzumab and chemotherapy for first-line treatment of advanced pancreatic cancer patients with KRAS G12D mutations. The study involves 32 patients with specific eligibility criteria and primary outcome measures such as objective response rate and secondary outcome measures like progression-free survival. The trial is set to begin in February 2025 and is expected to be completed by February 2028 in China. [Extracted from the article]

A clinical trial, NCT06768905, is being conducted to assess the safety, efficacy, and tolerability of a single 50 mCi dose of 131I-Apamistamab followed by axicabtagene ciloleucel infusion in patients with Relapsed or refractory (R/R) Diffuse large B-cell lymphoma (DLBCL). The study involves a 6-patient safety run-in to evaluate safety measures. The trial aims to determine the impact of this treatment regimen on patients with DLBCL, with a primary completion date set for May 31, 2028. [Extracted from the article]

The article discusses a clinical trial, NCT06775912, conducted by Nanjing Bioheng Biotech Co., Ltd., focusing on evaluating the safety and efficacy of RD06-05 in patients with autoimmune diseases such as SLE, SSc, AAV, IIM, NMOSD, MS, and MG. The study is an open clinical pharmacological translational research study with a primary completion date of January 1, 2027, and aims to assess the incidence of adverse events during treatment over a two-year period. The trial is currently recruiting participants in China and involves the administration of RD06-05 CART Cell Injection as part of CAR-T therapy for autoimmune diseases. [Extracted from the article]

A recent study conducted by researchers at Kindai University Faculty of Medicine compared the long-term efficacy and safety of entecavir (ETV) and tenofovir alafenamide (TAF) in patients with chronic hepatitis B. The study found that after 240 weeks, there were no significant differences in serum hepatitis B surface antigen levels, hepatitis B core-related antigen levels, estimated glomerular filtration rate, or incidence of hepatocellular carcinoma between the two groups. The research concluded that ETV and TAF have comparable efficacy and safety in treating chronic hepatitis B. [Extracted from the article]

A study conducted at Lorestan University of Medical Sciences in Khorramabad, Iran, explored the adjuvant capabilities of C-phycocyanin and phycocyanobilin, derived from Spirulina, in conjunction with the Hepatitis B vaccine. The research found that these compounds enhanced the humoral immune response, leading to increased expression of Hepatitis B surface antibodies. The study suggests that these novel adjuvants have the potential to improve the efficacy of the Hepatitis B vaccine and could be further evaluated with other vaccines. [Extracted from the article]

The article discusses a clinical trial, NCT06771154, focusing on the treatment of advanced recurrent/metastatic endometrial cancer. The study aims to evaluate the efficacy and safety of Adebelimab combined with Carboplatin/Paclitaxel treatment, followed by maintenance therapy with or without Apatinib. The trial will explore the Progression-Free Survival (PFS) and Overall Survival (OS) of patients with specific molecular characteristics, providing new precision treatment options for individuals with recurrent and metastatic endometrial cancer. [Extracted from the article]

A case report from Shenzhen, People's Republic of China, discusses the successful treatment of an 8-month-old infant with chronic hepatitis B cirrhosis using a combination therapy approach. The treatment involved a series of medications over several years, resulting in the functional cure of the child. This research provides valuable insights into the diagnosis and treatment of chronic hepatitis B virus-infected infants and young children, highlighting the potential for durable functional cure with individualized therapy. [Extracted from the article]

A patent application has been filed for a fusion protein that combines the SARS-CoV-2 spike protein with a hepatitis B surface antigen, aiming to develop a new vaccine against COVID-19. The fusion protein self-assembles into nanoparticles that could potentially elicit a strong and long-lasting immune response when administered to mammalian subjects. This innovative approach seeks to address the ongoing need for effective and improved COVID-19 vaccines. [Extracted from the article]

A study conducted by researchers at Grigore T. Popa University of Medicine and Pharmacy in Romania focused on the prevalence, risk factors, and outcomes of Hepatitis D (HDV) among vulnerable communities in the country. The research, which screened 320,000 individuals across 24 counties, found that HDV co-infection was more prevalent in socially disadvantaged groups such as rural residents, the Roma community, and those lacking health insurance. The study highlighted the urgent need for targeted public health interventions, including enhanced screening, education, and access to antiviral therapies to address the significant burden of HBV/HDV co-infection in Romania. [Extracted from the article]

A recent report from Huazhong University of Science and Technology discusses the challenges in achieving a complete cure for chronic hepatitis B due to the persistence of the virus even after hepatitis B surface antigen loss. The researchers emphasize the importance of follow-up and surveillance post-HBsAg loss to prevent recurrence, reactivation, cirrhosis, and hepatocellular carcinoma. The study highlights the need for effective surveillance strategies and further research to improve long-term outcomes for patients with chronic hepatitis B. [Extracted from the article]

Researchers at Sun Yat-sen University conducted a study on chronic hepatitis B patients treated with nucleotide analogs (NAs) alone or in combination with polyethylene glycol interferon (PEG-IFN). They found that the HBsAg clearance rate was significantly higher in the NAs plus PEG-IFN group compared to the NAs group. The study identified HBsAg, alanine aminotransferase (ALT) at week 24, and ALT change values from baseline to week 24 as predictors of HBsAg seroclearance in these patients. This research highlights the clinical value of NAs plus PEG-IFN therapy for treating chronic hepatitis B and introduces ALT change values as a novel predictor of treatment efficacy. [Extracted from the article]

A study conducted at Universitas Muslim Indonesia in Makassar, Indonesia, identified microRNA-3145 (miR-3145) as a potential therapeutic target for hepatitis B virus (HBV). The research found that miR-3145 downregulated the hepatitis B virus S (HBS) antigen and hepatitis B virus X (HBX), inhibiting viral replication. The study suggests that miR-3145-3p, along with small molecules targeting its binding sites, could be a promising candidate for HBV treatment. For more information, the full article is available in Frontiers in Microbiology. [Extracted from the article]

Researchers from the Department of Microbiology in Uttarakhand, India, conducted a study on chronic hepatitis B virus (HBV) infection in patients on entecavir therapy. The study aimed to evaluate quantitative HBV DNA and hepatitis B e antigen (HBeAg) titers in these patients and determine the rate of HBsAg-positive cases among suspected hepatitis patients. The research found a low prevalence of chronic HBV virus infection, with 4.1% of individuals testing positive for HBsAg, and a subset of these individuals experiencing chronic illness with positive HBeAg, elevated ALT enzyme levels, and positive HBV DNA. The study was published in the Asian Journal of Medical Sciences and conducted at MG hospital in Bhilwara, Rajasthan, with a total of 87,600 patients screened. [Extracted from the article]

A recent study conducted by researchers at the University of Babylon in Iraq focused on the immunological response of purified human peripheral blood mononuclear cells to somatic antigens of methicillin-resistant Staphylococcus aureus (MRSA) and hepatitis B virus (HBV) vaccine. The study found that the gene expression of forkhead box protein-3 (FOXP3), a regulatory gene for immune cells, significantly increased in response to MRSA-somatic antigens and HBV vaccine. This research highlights the importance of understanding the immunological responses to different antigens for optimal vaccine efficacy. For more information, the full article can be accessed through the Medical Journal of Babylon. [Extracted from the article]

The article discusses a phase III clinical trial, NCT06747455, evaluating the efficacy and safety of therapeutic BCG for preventing postoperative recurrence of non-muscle-invasive bladder cancer in individuals aged 18 and older. The study aims to assess the effectiveness and safety of BCG in treating intermediate- and high-risk bladder cancer after tumor resection. The trial design includes a randomized, double-blind, active-controlled approach with 438 participants, focusing on pharmacodynamic profiles and recurrence-free survival rates. The study is not yet recruiting participants and is expected to be completed by December 31, 2028. [Extracted from the article]

The article discusses a clinical trial, NCT06749054, evaluating the use of lenacapavir (LEN) in combination with other medications for adolescents and children with HIV-1 who have been previously treated. The study aims to assess the safety, tolerability, and efficacy of long-acting LEN, both as an injection and an oral pill, in this population. The primary objectives include evaluating the pharmacokinetics and safety of LEN in combination with an optimized background regimen in treatment-experienced pediatric participants with HIV-1. The trial is set to be completed by March 31, 2026, and focuses on key inclusion and exclusion criteria for participants. [Extracted from the article]

A study conducted by researchers at the Faculty of Applied Health Sciences in Nigeria investigated the prevalence of hepatitis B virus (HBV) infection among pregnant women. The study found an overall prevalence of 6.0%, with 3.5% overt and 2.5% occult infections. Risk factors such as blood transfusion, cigarette exposure, and alcohol consumption were associated with HBV infection, highlighting the importance of HBV DNA testing in screening protocols to improve antenatal care and prevention strategies. [Extracted from the article]

Researchers from Makerere University College of Health Sciences conducted a study on the serological status of hepatitis B virus (HBV) exposure among children under 5 and aged 15-17 in Kampala, Uganda. The study found that a large proportion of vaccinated children may be at risk of HBV infection, especially adolescents, due to low levels of detectable antibodies. The researchers suggest that a booster dose of the Hepatitis B Vaccine may be necessary for adolescents to improve protection against HBV. [Extracted from the article]